Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Romain Coriat, Hervé Gouya, Olivier Mir, Stanislas Ropert, Olivier Vignaux, Stanislas Chaussade, Philippe Sogni, Stanislas Pol, Benoit Blanchet, Paul Legmann, François Goldwasser
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/e825f27aca244bd4af209b233c81e4e9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares